Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.70 |
| ▸ | ANPEP | P15144 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768839 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13937654 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13494285 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL15482322 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13841888 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL19898335 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13868207 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL25594421 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL26967475 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13962503 | 0.88 | MMP2 (0.56) | MMP2ANPEPPOLBNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119505138-A | Chiral covalent organic framework mimic enzyme catalyst and preparation method and application thereof | 浙江工业大学 | 2025-02-25 | — | — | CN | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4257191-A2 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2020-01-30 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| CN-101602795-B | Cyclohexalipopeptide amine antifungal compound, salts and preparation method thereof | ARMY MEDICAL UNIV. NO.2, CHINESE PLA (CN) | 2011-12-21 | — | — | CN | disclosed |
| US-20110251403-A1 | Method for Manufacturing Hydroxyl Group Substitution Product | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251403-A1 | Method for Manufacturing Hydroxyl Group Substitution Product | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| CN-101602795-A | Cyclohexalipopeptideamine amine antifungal compound and its esters and preparation method | UNIV PLA 2ND MILITARY MEDICAL (CN) | 2009-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | MMP2 2616/4885ANPEP 2234/4885CYP1A2 2209/4885 |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | MMP2 4573/4885ANPEP 4168/4885CYP1A2 3277/4885 |
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | MMP2 145/4885ANPEP 95/4885CYP1A2 2015/4885 |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | MMP2 2459/4885ANPEP 93/4885CYP1A2 4337/4885 |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, HTRA2 | MMP2 145/4885ANPEP 279/4885CYP1A2 1804/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | MMP2 145/4885ANPEP 95/4885CYP1A2 2015/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | MMP2 2459/4885ANPEP 93/4885CYP1A2 4337/4885 |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | HTRA1, ALDH1A2, HTRA2 | MMP2 145/4885ANPEP 279/4885CYP1A2 1804/4885 |
| US-20110251403-A1 | Method for Manufacturing Hydroxyl Group Substitution Product | PHF2, XDH, YIF1A | MMP2 1058/4885ANPEP 355/4885CYP1A2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.